Seladin-1 and testicular germ cell tumours: New insights into cisplatin responsiveness

Journal of Pathology

Volumn 219, Issue 4, 2009, Pages 491-500

  Nuti, Francesca ^a   Luciani, Paola ^a   Marinari, Eliana ^a   Erdei, Edit ^b   Bak, Mihaly ^c   Deledda, Cristiana ^a   Rosati, Fabiana ^a   Mazzinghi, Benedetta ^a   Danza, Giovanna ^a   Stoop, Hans ^d   Looijenga, Leendert H J ^d   Peri, Alessandro ^a   Serio, Mario ^a   Krausz, Csilla ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Cisplatin; Male infertility; Seladin 1; Testicular cancer; TGCT

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CISPLATIN; MESSENGER RNA; PROTEIN; RETINOIC ACID; SELADIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL DIFFERENTIATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; GERM CELL TUMOR; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SEMINOMA; TESTIS TERATOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS, GERM CELL AND EMBRYONAL; NERVE TISSUE PROTEINS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA, SMALL INTERFERING; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 72249096230     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2622     Document Type: Article

References (38)

1. Adami HO, Bergstrom R, Mohner M, Zatonski W, Storm H, Ekbom A, et al. Testicular cancer in nine northern European countries. Int J Cancer 1994;59:33-38. (Pubitemid 2140078)
2. Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10:19-28. (Pubitemid 17081837)
3. Weissbach I, Bussar-Maatz R. [Pathogenesis, diagnosis and therapy of testicular tumors]. Urologe A 1996;35:163-172.
4. Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. Nature Rev Cancer 2005;5:210-222. (Pubitemid 40314952)
5. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005;18(Suppl 2):S61-S79.
6. Jorgensen N, Rajpert-De Meyts E, Graem N, Muller J, Giwercman A, Skakkebaek NE. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest 1995;72:223-231.
7. Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003;63:7674-7678. (Pubitemid 37466695)
8. Looijenga LH, Oosterhuis JW. Pathogenesis of testicular germ cell tumours. Rev Reprod 1999;4:90-100. (Pubitemid 29245933)
9. Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000;60:1475-1482. (Pubitemid 30183409)
10. Porcaro AB, Antoniolli SZ, Maffei N, Beltrami P, Bassetto MA, Curti P. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature. Arch Ital Urol Androl 2002;74:81-85. (Pubitemid 34773910)
11. Al Ghamdi AM, Jewett MA. Stage I nonseminomatous germ cell tumors: the case for management by risk stratification. Can J Urol 2005;12(Suppl 1):62-65; discussion 103-104.
12. Peckham M. Testicular cancer. Acta Oncol 1988;27:439-453.
13. Perrotti M, Ankem M, Bancilla A, de Carvalho V, Amenta P, Weiss R. Prospective metastatic risk assignment in clinical stage I nonseminomatous germ cell testis cancer: a single institution pilot study. Urol Oncol 2004;22:174-177. (Pubitemid 38950620)
14. Classen J, Souchon R, Hehr T, Bamberg M. Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol 2001;127:475-481. (Pubitemid 32662504)
15. Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat Rev 2002;28:237-253. (Pubitemid 35439438)
16. Jones RH, Vasey PA. Part II: testicular cancer - management of advanced disease. Lancet Oncol 2003;4:738-747. (Pubitemid 37527209)
17. Oosterhof GO, Verlind J. Testicular tumours (nonseminomatous). BJU Int 2004;94:1196-1201.
18. Masters JR, Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Rev 2003;3:517-525. (Pubitemid 37328839)
19. Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, et al. Mutations in the 3beta-hydroxysterol delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001;69:685-694. (Pubitemid 32868514)
20. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez- Isla T, Behl C, et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000;20:7345-7352. (Pubitemid 30747430)
21. Sarkar D, Imai T, Kambe F, Shibata A, Ohmori S, Siddiq A, et al. The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. J Clin Endocrinol Metab 2001;86:5130-5137. (Pubitemid 33070226)
22. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by seladin-1. Nature 2004;432:640-645. (Pubitemid 39626272)
23. Luciani P, Ferruzzi P, Arnaldi G, Crescioli C, Benvenuti S, Nesi G, et al. Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 2004;89:1332-1339. (Pubitemid 38368433)
24. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, et al. Expression of the antiapoptotic gene seladin- 1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005;90:6156-6161. (Pubitemid 41613670)
25. Fuller PJ, Alexiadis M, Jobling T, McNeilage J. Seladin-1/ DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours. Clin Endocrinol (Oxford) 2005;63:111-115. (Pubitemid 40966411)
26. Peri A, Serio M. Neuroprotective effects of the Alzheimer's disease-related gene seladin-1. J Mol Endocrinol 2008;41:251-261.
27. Benvenuti S, Luciani P, Cellai I, Deledda C, Baglioni S, Saccardi R, et al. Thyroid hormones promote cell differentiation and up-regulate the expression of the seladin-1 gene in in vitro models of human neuronal precursors. J Endocrinol 2008;197:437-446. (Pubitemid 351696257)
28. Di Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M, Chiodini E, et al. DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. Int J Cancer 2005;115:224-230. (Pubitemid 40586730)
29. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006;66:5012-5020. (Pubitemid 43844921)
30. Bonaccorsi L, Luciani P, Nesi G, Mannucci E, Deledda C, Dichiara F, et al. Androgen receptor regulation of the seladin- 1/DHCR24 gene: altered expression in prostate cancer. Lab Invest 2008;88:1049-1056.
31. Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 1984;103:285-293.
32. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, et al. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 2006;29:471-479.
33. Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG, et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999;81:620-628. (Pubitemid 29203062)
34. Luciani P, Deledda C, Rosati F, Benvenuti S, Cellai I, Dichiara F, et al. Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology 2008;149:4256-4266.
35. Benvenuti S, Luciani P, Vannelli GB, Gelmini S, Franceschi E, Serio M, et al. Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. J Clin Endocrinol Metab 2005;90:1775-1782. (Pubitemid 40464051)
36. Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, et al. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 2005;97:314-322. (Pubitemid 41216135)
37. Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, van Gurp RJ, et al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 2006;66:290-302. (Pubitemid 43166035)
38. Looijenga LH, Stoop H, Hersmus R, Gillis AJ, Wolter Oosterhuis J. Genomic and expression profiling of human spermatocytic seminomas: pathogenetic implications. Int J Androl 2007;30:328-335; discussion 335-1326 (Pubitemid 47254422)